Pierfranco Conte
Overview
Explore the profile of Pierfranco Conte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
224
Citations
9291
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
van Mackelenbergh M, Loibl S, Untch M, Buyse M, Geyer Jr C, Gianni L, et al.
J Clin Oncol
. 2023 Apr;
41(16):2998-3008.
PMID: 37075276
Purpose: The achievement of pathologic complete response (pCR) is strongly prognostic for event-free survival (EFS) and overall survival (OS) in patients with early breast cancer (EBC), and adapting postneoadjuvant therapy...
12.
Dieci M, Bisagni G, Bartolini S, Frassoldati A, Vicini R, Balduzzi S, et al.
NPJ Breast Cancer
. 2023 Apr;
9(1):24.
PMID: 37045875
No abstract available.
13.
Squifflet P, Saad E, Loibl S, van Mackelenbergh M, Untch M, Rastogi P, et al.
J Clin Oncol
. 2023 Mar;
41(16):2988-2997.
PMID: 36977286
Purpose: Pathologic complete response (pCR) has prognostic importance and is frequently used as a primary end point, but doubts remain about its validity as a surrogate for event-free survival (EFS)...
14.
Senkus E, Delaloge S, Domchek S, Conte P, Im S, Xu B, et al.
Int J Cancer
. 2023 Mar;
153(4):803-814.
PMID: 36971103
In the primary analysis of the phase III OlympiAD trial, olaparib significantly prolonged progression-free survival (PFS) vs chemotherapy treatment of physician's choice (TPC) in patients with germline BRCA-mutated (gBRCAm), HER2-negative...
15.
Garufi G, Carbognin L, Sperduti I, Miglietta F, Dieci M, Mazzeo R, et al.
Ther Adv Med Oncol
. 2023 Mar;
15:17588359221138657.
PMID: 36936199
Background: Given the low chance of response to neoadjuvant chemotherapy (NACT) in luminal breast cancer (LBC), the identification of predictive factors of pathological complete response (pCR) represents a challenge. A...
16.
Robson M, Im S, Senkus E, Xu B, Domchek S, Masuda N, et al.
Eur J Cancer
. 2023 Mar;
184:39-47.
PMID: 36893711
Background: In the Phase III OlympiAD study, olaparib significantly prolonged progression-free survival versus chemotherapy treatment of physician's choice (TPC) in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor...
17.
Giustiniani A, Danesin L, Pezzetta R, Masina F, Oliva G, Arcara G, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831693
The diagnosis and side effects of breast cancer (BC) treatments greatly affect the everyday lives of women suffering from this disease, with relevant psychological and cognitive consequences. Several studies have...
18.
Antonazzo I, Cortesi P, Miceli Sopo G, Mazzaglia G, Conte P, Mantovani L
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831518
Background: This study was aimed at estimating the appropriate price of tucatinib plus trastuzumab and capecitabine (TXC), as third-line treatment, in HER2 breast cancer (BC) patients from the Italian National...
19.
Dieci M, Bisagni G, Bartolini S, Frassoldati A, Vicini R, Balduzzi S, et al.
NPJ Breast Cancer
. 2023 Feb;
9(1):6.
PMID: 36739285
The optimal adjuvant endocrine therapy for HR-positive/HER2-positive breast cancer patients is unknown. We included in this analysis 784 patients with HR-positive/HER2-positive BC from the randomized ShortHER trial of adjuvant trastuzumab...
20.
Corrao G, Alquati G, Apolone G, Ardizzoni A, Buzzetti G, Canonica G, et al.
Glob Reg Health Technol Assess
. 2023 Jan;
8:134-139.
PMID: 36627865
No abstract available.